Table 1 FDA approved anti-angiogenic agents for the treatment of solid tumors

Bevacizumab

Monoclonal Antibody

VEGF

Ramucirumab

Monoclonal Antibody

VEGFR2

Ziv-Aflibercept

Fusion Protein

VEGF, VEGF-B, PlGF

Sorafenib

TKI

RAF/MEK/ERK, VEGFR 1–3, PDGFR- β, c-KIT, FLT3, RET

Sunitinib

TKI

VEGFR1 and 2, PDGFR-α and -β, c-KIT, RET, CSF1R, FLT3

Vandetanib

TKI

VEGFR2 and 3, EGFR, RET

Pazopanib

TKI

VEGFR 1–3, PDGFR-α and -β, FGFR-1 and − 3, c-KIT

Axitinib

TKI

VEGFR 1–3, PDGFR-α and -β, c-KIT

Regorafenib

TKI

VEGFR1–3

Lenvatinib

TKI

VEGR1–3, FGFR1–4, PDGFR- α, c-KIT, RET

Cabozatinib

TKI

VEGFR2, AXL, RET, MET, c-KIT, FLT-3